Vial sizes vary by vendor. Smaller bottles are usually 3 mL; larger bottles are often 10 mL. Match the label on the vial you actually bought, then use the calculator below if you need to adjust.
Overview
Semaglutide is a GLP-1 receptor agonist widely used for weight management and glycemic control.
Preparation
Recon: 5 mg vial + 2 mL BAC (2.5 mg/mL).
Protocol
| Period | Dose | Units (@ 2.5 mg/mL) | Frequency |
|---|---|---|---|
| Weeks 1-4 | 0.25 mg | 10 u | 1x/week |
| Weeks 5-8 | 0.5 mg | 20 u | 1x/week |
| Weeks 9-12 | 1 mg | 40 u | 1x/week |
| Weeks 13-16 | 1.7 mg | 68 u | 1x/week |
| Weeks 17-20 | 2.4 mg | 96 u | 1x/week |
Cycle
12-16 weeks on, 4 weeks off.
Research coverage
Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on Semaglutide Protocol.
- Semaglutide STEP UP: Thigh Muscle and Fat Infiltration Sep 21, 2026
A STEP UP analysis found semaglutide reduced thigh muscle fat infiltration while preserving sit-to-stand function — a look at muscle quality, not just mass.
- How Structural Design Defines Next-Generation GLP-1 Analogs Sep 15, 2026
A structural overview of how DPP-4 resistance, lipidation, signaling bias, and multi-receptor agonism produce progressively more sophisticated incretin therapies.
- GLP-1 Agonists for MASH Fibrosis: an Overview Sep 8, 2026
A Cell Reports Medicine review surveys incretin-based therapies for MASH fibrosis — from FDA-approved semaglutide to emerging dual and triple GLP-1 agonists.
- IDE and GLP-1 Degradation: A New Stability Pathway Sep 1, 2026
- What Happens to Muscle When Semaglutide Drives Weight Loss Aug 31, 2026
A 12-month semaglutide study found absolute lean mass fell while a muscle quality index improved and handgrip strength stayed preserved in participants.
- Semaglutide, Muscle Loss, and the Protein Question Aug 28, 2026
A 12-month routine-care study shows absolute lean mass falls with semaglutide while reference-based muscle status improves — and a parallel review argues protein intake deserves more…
- Semaglutide and NAION: What the New Correspondence Shows Aug 28, 2026
New correspondence in JAMA Ophthalmology argues over the data and temporal risk in semaglutide–NAION analyses — the exchange itself is a reminder that the safety question is a methods…
- Semaglutide vs. Bariatric Surgery for Liver Disease Aug 28, 2026
A 92-patient observational comparison over 72 weeks finds semaglutide and sleeve gastrectomy both improve noninvasive liver markers in MASLD — with a hint that semaglutide's liver…